dr. langer on the benefit of durvalumab in stage iii nsclc
Published 5 years ago • 720 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
2:34
dr. langer on practice-changing pacific data in stage iii nsclc
-
6:50
implications for using durvalumab in stage 3 nsclc
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
0:53
dr. schwartz on the results of the pacific trial
-
7:44
immunotherapy in stage iii nsclc
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
4:16
reactions to the pacific trial in stage iii nsclc
-
7:44
immunotherapy in stage iii nsclc
-
1:42
dr. feldman on the future of durvalumab and tremilimumab in nsclc
-
5:14
tips for managing nsclc patients on durvalumab therapy
-
0:47
dr. feldman on durvalumab for patients with lung cancer
-
1:20
dr. simon on durvalumab for patients with lung cancer
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
8:23
the pacific trial in stage 3 nsclc
-
3:12
concurrent chemoradiotherapy in stage iii nsclc
-
4:41
immunotherapy for operable nsclc
-
6:00
locally advanced nsclc: approaching the pacific trial
-
5:06
surgery in the context of immunotherapy for locally advanced nsclc
-
11:38
immunotherapy for management of stage 3b nsclc